**CATHERINE SOHN, Pharm.D, Head, Corporate Development at BioAxone Biosciences,** is a pharmacist, biopharmaceutical executive, adjunct professor, and a Certified Licensing Professional. Additionally, she serves as non-executive Chairman of BioEclipse Therapeutics, a private, immuno-oncology company and is an independent Director on the Board of Directors of Jazz Pharmaceuticals (NASDAQ: JAZZ), Landec Corp (NASDAQ: LNDC) and Dohmen Life Science Services. She holds the position of Adjunct Professor at the University of California, San Francisco and serves on the board of directors of the not-for-profit World Affairs Council of Philadelphia. Sohn has 30 years of industry experience in business strategy, strategic product development, commercial leadership of launch executions and global business development. Prior to BioAxone, she was senior vice president of worldwide business development at GlaxoSmithKline and before that vice president of Worldwide Strategic Product Development for the Cardiovascular, Metabolic & Pulmonary Therapeutic Areas at SmithKline Beecham. As an entrepreneur within a large corporation, Sohn established the US Vaccine Business Unit and led the launch of SB's first vaccine in the US and subsequently, led the U.S. launch of the company's $1 billion CNS product. Sohn received the ‘Distinguished Alumnus’ award from UCSF in 2000, was named ‘Woman of the Year’ by the HBA in 2003. and the HBA Euro-Excellence Award (2012). In 2016, she was named one of the PharmaVoice 100 Most Inspiring People in the life-sciences industry. Sohn earned a Doctor of Pharmacy degree from the University of California, San Francisco and a Certificate of Professional Development from The Wharton School at the University of Pennsylvania.